leadf
logo-loader
viewVolitionRx

Volition Rx receives $4 million in non-dilutive financing to support development of Belgian operations

The additional funding consists of a cash grant of $1.3 million and $2.7 million in loans from the Walloon Region and Namur Invest, Belgium

VolitionRx -
To date, the group has received approximately $13 million in non-dilutive funding from agencies in the Walloon region

VolitionRx Limited (NYSEAMERICAN:VNRX) announced Wednesday that it has received an additional $4 million in non-dilutive funding from a Belgian region.

The funds will go towards developing the epigenetics company’s Silver One production facility in Belgium, where the Austin, Texas-based company is working on diagnostic blood tests.

Volition said the additional funding consists of a cash grant of $1.3 million and $2.7 million in loans from the Walloon Region and Namur Invest, Belgium.

READ: VolitionRx welcomes Veterinary Centers of American executive Tom Butera to its board of directors

To date, the group has received approximately $13 million in non-dilutive funding from agencies in the Walloon region of the country.

Volition CEO Cameron Reynolds told shareholders that non-dilutive funding is a key part of the firm’s financing strategy as it provides additional cash at favorable terms to support the company's continued development.

“(This) latest funding takes the total non-dilutive funding to-date from all sources to over $15 million," Reynolds said in a statement. "We are delighted with the great progress we are making on so many fronts and look forward to achieving many milestones throughout this year."

Financing details

The financing consisted of a grant worth 1.1 million Euros (US$1.3 million) from the Walloon Region to help support a project that examines epigenetic modifications of nucleosomes associated with cancer.

A loan of 929,432 Euros (US$1.1 million) from the Walloon Region will go towards research and technology transfer for the production of recombinant nucleosomes. Repayment terms are spilt into two parts: repayment independent of revenues (limited to 30% from 2022 to 2036) and repayment revenue dependent at 4.34% of revenue generated on this product from launch up to 2036.

Another unsecured loan from the Walloon Region of 495,000 Euros (US$600,000) will support the analysis of tumor DNA using an innovative nucleosome immunoprecipitation method. Repayment terms are also split in two parts: repayment independent of revenues (limited to 30% from 2023 to 2034) and repayment revenue dependent at 2.89% of revenue generated on this product from launch up to 2032.

Namur Invest also provided a loan of 830,000 Euros (US$1 million) to support the purchase and retrofit of the Silver One production facility. The loan bears an interest rate of 4% and is repayable over ten years ending March 2031.

Volition's research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: VolitionRx

Price: 4.08 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $215.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

VolitionRx Limited ends its 3Q with $21M in the bank, looks forward to...

VolitionRx Limited (NYSE AMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the group finished its third quarter with around $21M in the bank compared with $17M at the end of 2019. Reynolds also discussed upcoming milestones including the preparing to launch its new product, Nu.Q™ Vet Cancer...

on 11/13/2020

2 min read